Status:

UNKNOWN

Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy

Lead Sponsor:

National Taiwan University Hospital

Collaborating Sponsors:

National Science and Technology Council, Taiwan

Conditions:

Helicobacter Pylori Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Currently, a 10-day concomitant therapy has been reported to be equally effective and safe to the 10-day sequential therapy for 1st-line anti-Helicobacter pylori(H. pylori) therapy. To our knowledge, ...

Detailed Description

Patients, aged 18, having H. pylori-positive chronic gastritis with/without peptic ulcers will be recruited. All undergo endoscopy with biopsy before treatment. Four to eight weeks after termination o...

Eligibility Criteria

Inclusion

  • patients having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 18 years and are willing to received eradication therapy.

Exclusion

  • pregnant or nursing woman
  • serious concomitant illness and malignant tumor of any kind
  • history of hypersensitivity to test drugs
  • serious bleeding during the course of this ulcer
  • previous gastric surgery
  • receiving bismuth salts, proton pump inhibitors, or antibiotics in the previous month.

Key Trial Info

Start Date :

November 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2013

Estimated Enrollment :

204 Patients enrolled

Trial Details

Trial ID

NCT01265069

Start Date

November 1 2010

End Date

December 1 2013

Last Update

June 3 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Taiwan University Hospital

Taipei, Taiwan, 10043